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Background: Colorectal cancer (CRC) survival depends mostly on stage at the time of diagnosis. However,
symptom duration at diagnosis or treatment have also been considered as predictors of stage and survival. This
study was designed to: 1) establish the distinct time-symptom duration intervals; 2) identify factors associated with
symptom duration until diagnosis and treatment.
Methods: This is a cross-sectional study of all incident cases of symptomatic CRC during 2006–2009 (795 incident
cases) in 5 Spanish regions. Data were obtained from patients’ interviews and reviews of primary care and hospital
clinical records. Measurements: CRC symptoms, symptom perception, trust in the general practitioner (GP), primary
care and hospital examinations/visits before diagnosis, type of referral and tumor characteristics at diagnosis.
Symptom Diagnosis Interval (SDI) was calculated as time from first CRC symptoms to date of diagnosis. Symptom
Treatment Interval (STI) was defined as time from first CRC symptoms until start of treatment. Nonparametric tests
were used to compare SDI and STI according to different variables.
Results: Symptom to diagnosis interval for CRC was 128 days and symptom treatment interval was 155. No
statistically significant differences were observed between colon and rectum cancers. Women experienced longer
intervals than men. Symptom presentation such as vomiting or abdominal pain and the presence of obstruction
led to shorter diagnostic or treatment intervals. Time elapsed was also shorter in those patients that perceived their
first symptom/s as serious, disclosed it to their acquaintances, contacted emergencies services or had trust in their
GPs. Primary care and hospital doctor examinations and investigations appeared to be related to time elapsed to
diagnosis or treatment.
Conclusions: Results show that gender, symptom perception and help-seeking behaviour are the main patient
factors related to interval duration. Health service performance also has a very important role in symptom to
diagnosis and treatment interval. If time to diagnosis is to be reduced, interventions and guidelines must be
developed to ensure appropriate examination and diagnosis during both primary and hospital care.
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Colorectal cancer (CRC) is the second most frequent
cancer and the second leading cause of cancer death in
Europe [1]. CRC survival rates across the continent have
increased mainly due to improvements in diagnosis and
treatment with a mean survival rate of 56.2% at five
years according to European cancer registries [2]. Sur-
vival depends mostly on stage at the time of diagnosis
[3]. However, late diagnosis or treatment have also been
considered as predictors of stage and survival, although
these results are controversial [4-6].
Factors associated with the time interval between
symptom onset and diagnosis or treatment are not
sufficiently understood, regardless of whether they are
related to the patient, the GP or the hospital setting.
Theoretical frameworks used in cancer diagnosis re-
search conceptualized time intervals occurring between
phases of decision-making. [7,8]. These early models, re-
cently refined by Walters et al. [9], included four
intervals: ‘appraisal’, ‘help-seeking’ ‘diagnostic’ and ‘pre-
treatment’, in an attempt to represent the processes oc-
curring during each. In fact, the CRC diagnosis process
is complex and difficulties may arise at any point along
the clinical pathway. Firstly, the patient and his/her so-
cial context response, when faced with symptom onset,
could determine time elapsed before seeking help [10].
In this sense, the severity value given to a symptom, and
the attitudes when dealing with a possible cancer, can
lead to either early help-seeking or waiting for the
symptoms to clear up [11]. Moreover, in most cases, the
tumor appears with very common and non-specific
symptoms, and general practitioners (GPs) and second-
ary care specialists are required to differentiate between
patients whose symptoms may be due to cancer and
others whose symptoms are attributable to benign, tran-
sitory illness [12-14].
While there are recent rigorous studies on time dur-
ation to cancer diagnosis or treatment, much of the rele-
vant literature is old and presents methodological issues
that need to be taken into account such as different ways
of measuring symptom duration and accuracy in
recording symptom presentation [4,5].
Care continuity problems in CRC diagnosis have been
highlighted in several countries, and health authorities
advocate reduction in the time interval between suspi-
cion of CRC and diagnosis or treatment. Various
initiatives have been set up to identify those patients
with symptoms related to CRC that suggest a need for
prompt investigation [15,16].
In this study we try to address several issues. Firstly, to
identify the delays that may occur at various stages along
the clinical pathway in accordance with theoretical
models, the factors associated with symptom duration
and where there is greatest potential for improvement.Secondly, to overcome some of the problems identified
in our reviews with a wider spectrum of patients and
provide more accurate definitions of time intervals all
over the diagnosis pathway and symptom presentation.
The aims of the study are: 1) to establish the distinct
time-intervals to diagnosis and treatment; 2) to identify
factors associated with late diagnosis and treatment.
Methods
Setting and study population
This paper reports findings from a larger study whose
methods have been published elsewhere [17]. This is a
cross-sectional study carried out in 5 Spanish regions.
Briefly, subjects were consecutive incident cases of CRC
(IDC9 153 and 154), verified histologically, between
September 2006 and September 2008 and registered
with a GP. Prevalent or recurrent cases were excluded
as well as patients with multiple tumors and those diag-
nosed in private hospitals. For the present analysis,
non-symptomatic patients were also excluded (screening
detected cases, incidental findings).
Patients were identified at diagnosis through results of
histological findings from endoscopy or surgery and contacted
during the inpatient stage or oncology visit by their sur-
geon or oncologist who invited them to participate.
Measurements
Data were obtained from patient interviews together
with primary care and hospital clinical records review.
Each of the patients was interviewed after diagnosis
using a structured questionnaire during the inpatient
stage, oncology visit or, if this were not possible, at home
by a trained nurse or GP. Informed consent for study
participation and access to medical records was obtained
during the interview. In cases where the patient was
deceased or could not be interviewed for other reasons,
permission to review patient clinical records was obtained
from a close family member. Details about measurements
can be found in Additional file 1.
Interview measurements: Each patient was asked how
long he/she had been feeling unwell and given a check-
list to identify the type of symptom/s noted [18].
Symptoms spontaneously mentioned by the patient were
considered the initial symptom/s for that patient and the
date was recorded. Additional presenting symptoms
were recorded. Other variables were social class [19] and
demographic characteristics, perception of symptom ser-
iousness, disclosure of symptoms, help-seeking action,
doctor-patient relationship, and familial history of cancer.
Primary care measurements were: date of first symptom
and other symptoms, date of first contact with GP due to
CRC symptoms, examinations and visits before diagnosis
and their results, and date and information included in
the referral. Hospital record measurements were: tumor
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obstruction, date of first contact due to CRC symptoms,
date of diagnosis, service attending the patient, examinations
and visits before diagnosis and their results, and date and
type of treatment.
Symptom duration was divided into several intervals
Symptom Diagnosis Interval (SDI): from onset of first
CRC symptoms to date of diagnosis.
Symptom Treatment Interval (STI): from onset of first
CRC symptoms until start of treatment.
Patient Interval (PI): from onset of first CRC symptoms
to date of first consultation with a physician (GP or hos-
pital specialist).
Health Services Interval (HSI): Interval from 1st con-
tact with a physician to diagnosis.
Treatment interval (TI): Interval from date of diagno-
sis to date of treatment.
In order to calculate time intervals, it was necessary to
establish several definitions:
Date of onset of the first symptom/s was the one re-
ferred to by the patient. In the case of no interview, the
date of 1st symptom recorded in the primary health care
record or in the hospital record was used.
Date of diagnosis, i.e., date of first positive histology
report. Date of treatment, i.e., date of surgery, date of
preoperative or postoperative radiotherapy or chemo-
therapy or date of palliative treatment. For those patients
who did not receive any treatment, the date of the visit
closest to the decision not to treat the patient was
recorded.
Statistical analysis
The graphical analysis of interval times showed skewed
distributions confirmed with the Kolmogorov-Smirnov






Median (P25-P75) Median (P25-P75)
Colon & rectum 128 (57.5-257.5) 155 (84.0-283.5)
Colon 125 (59.0-258.0) 150 (80.0-280.5)
Rectum 121 (53.0-256.0) 153 (79.0-283.0)
N(%) N(%)
Colon & Rectum
< 1 month 110 (14.1) 59 (7.9)
1-3 months 190 (24.3) 152 (20.4)
3-6 months 207 (26.5) 215 (28.9)
6 month-1 year 165 (21.1) 184 (24.7)
> 1 year 109 (14.0) 134 (18.0)median and 25–75 percentiles. To assess the rela-
tionship between the different types of symptom interval
duration and the observed variables, we used the Mann–
Whitney U test for dichotomous variables and Kruskal-
Wallis test for those variables with more than two
categories. In order to avoid symptoms that could not be
related to CRC, no more than a 24-month interval be-
tween symptom and diagnosis was accepted. Nineteen
patients (0.3%) had a SDI of 24 months and twenty-one
(0.7%) in the case of STI. All statistical analyses were
performed using SPSS v.15.0.
This Study was approved by the Primary Health Care
Committee of each health district and by the Ethical and
Clinical Research Committee of each participating region.
Results
A total of 950 incident colorectal cancer patients were
recruited. For the present study, 155 asymptomatic
patients were excluded; 94 (9.9%) screen detected and 61
(6.4%) incidental findings. Finally, 795 symptomatic
cases were included; 481 (60.5%) were colon cases and
314 (39.5%) rectum. Hospital record information was
available for all patients and primary care records for
780 patients (98.1%). In 66 (8.3%) patients the interview
was not completed. The interview was completed during
inpatient stay in 310 patients (44.7%), prior to surgery in
48 (6.9%), during outpatients visits in 267 (38.5%) and
69 (9.9%) at home.
Various time intervals are shown in Table 1. The median
SDI and STI for CRC were 128 and 155 days respectively.
Three months following symptom onset, four in ten
patients are diagnosed and nearly three treated. No
statistically significant differences were observed in SDI be-
tween colon and rectum, 125 (59–258) vs. 121 (53–256)
respectively (p=0.51), or in STI 150 (80–280.5) vs. 153
(79–283), (p=0.08). Most of the treatment interval stemmedptom-patient first contact





Median (P25-P75) Median (P25-P75) Median (P25-P75)
19 (3–83) 66 (25–159) 22 (8–37)
18 (3–74) 64 (23–164.5) 18 (4–33)
20 (3–83.2) 62 (22–156) 22 (8–38)
N(%) N(%) N(%)
483 (61.7) 245 (30.8) 501 (65.8)
139 (17.8) 235 (29.6) 234 (30.7)
80 (10.2) 149 (18.7) 16 (2.1)
35 (4.5) 109 (13.7) 9 (1.2)
46 (5.9) 57 (7.2) 1 (0.1)
Esteva et al. BMC Cancer 2013, 13:87 Page 4 of 13
http://www.biomedcentral.com/1471-2407/13/87from health services time interval to diagnosis and less from
the patient or interval from diagnosis to treatment.
Women present higher diagnostic time intervals than
men. No significant differences in symptom duration
intervals were found for age, level of education, social
class or marital status. Finally, those patients with family
history of cancer had longer diagnosis and treatment


















Illiterate-incomplete primary 106 (14.6)
Primary education 402 (55.3)
Secondary education 101 (13.9)
High School 72 (9.9)
University education 46 (6.3)
P
Social Class
Class I & II 58 (9.0)
Class III 154 (23.8)
Class IVa 208 (32.2)
Class IVb 102 (15.8)
Class V 124 (19.2)




PConcerning initial symptoms (Table 3), the presence of
abdominal pain, vomiting and intestinal obstruction are
associated with shorter time between symptom onset
and diagnosis or treatment. There were no differences
between SDI and STI with regard to other symptoms or
the number of symptoms at presentation. Moreover, we
observed a clear gradient in the duration of SDI depend-








113 (51.0-246.0) 144 (84.0-273.7)
153 (73.0-274.0) 175 (93.0-289.0)
<0.01 0.07
171.0 (127.2-246.2) 149.0 (104.0-214.0)
163.0 (87.5-295.5) 133.0 (60.5-254.5)
137.0 (83.0-255.2) 112.5 (49.0-224.7)
159.5 (84.0-326.2) 132.0 (62.5-289.5)
0.34 0.20
130 (48.0-342.0) 157.5(75.5-359.0)
120 (57.0-245.5) 153.0 (89.0-272.0)
154 (77.5-306.5) 178.0 (96.0-336.7)
0.09 0.40
127.0 (39.0-265.5) 151.0 (73.0-282.0)
132.0 (66.0-270.0) 163.0 (93.2-295.7)
130.0 (70.5-214.5) 160.0 (88.5-264.5)
122.0 (47.0-311.0) 155.0 (79.0-343.0)
103.5 (34.5-232.2) 127.0 (55.5-260.0)
0.78 0.78
145.5 (67.7-267.5) 146.5 (80.5-313.5)
133.0 (63.0-320.5) 163.0 (89.5-354.0)
120.0 (58.5-223.5) 154.5 (93.5-255.0)
131.0 (66.5-244.5) 170.5 (92.2-296.2)
128.0 (48.5-229.0) 155.0 (77.5-257.0)
0.86 0.73
138.0 (70.0-276.0) 169.5 (96.2-313.7)
124.5 (56.0-227.0) 147.0 (78.5-259.5.2)
0.07 0.01
Table 3 Relationship with presenting symptom, help-seeking behaviour and trust in their GP
N (%) Symptom diagnostic interval Symptom treatment interval
median (P25-P75) median (P25-P75)
(days) (days)
Abdominal pain
Yes 195 (27.3) 117.0 (41.0-220.0) 137.0 (58.0-252.0)
No 520 (72.7) 133.0 (66.0-280.0) 171.0 (96.7-314.0)
P 0.01 <0.001
Other pain
Yes 50 (7.0) 122.5 (66.7-359.0) 159.5 (98.7-394.5)
No 665 (93.0) 130.0 (59.0-259.0) 159.0 (87.0-288.0)
P 0.70 0.52
Rectal Bleeding
Yes 285 (39.9) 118.0 (51.5-260.0) 169.0 (89.0-298.0)
No 430 (60.1) 136.0 (63.0-263.0) 154.0 (85.5-282.5)
P 0.38 0.43
Changes in bowel habits
Yes 273 (38.2) 128.0 (57.0-229.0) 152.0 (86.7-275.0)
No 442 (61.8) 130.5 (61.7-275.2) 162.0 (89.0-317.0)
P 0.28 0.28
Vomiting
Yes 24 (3.4) 49.0 (10.2-134.7) 71.0 (13.0-154.0)
No 691 (96.6) 131.0 (63.0-264.5) 161.5 (91.0-291.2)
P <0.001 <0.001
Tenesmus
Yes 38 (5.3) 146.0 (51.0-272.0) 181.0 (93.5-325.5)
No 677 (94.7) 130.0 (60.0-262.2) 155.5 (87.0-286.2)
P 0.67 0.40
Loss of appetite
Yes 49 (6.9) 133.0 (45.0-192.0) 135.0 (59.2-214.7)
No 666 (93.1) 130.0 (61.0-268.0) 159.0 (89.0-296.0)
P 0.24 0.10
Loss of weight
Yes 57 (8.0) 121.0 (58.5-200.0) 154.0 (92.0-233.0)
No 658 (92.0) 130.0 (60.0-271.0) 159.0 (87.5-299.5)
P 0.31 0.36
Fatigue
Yes 97 (13.6) 145.0 (72.0-266.0) 172.0 (93.0-295.0)
No 618 (86.4) 128.0 (56.0-261.0) 155.0 (86.7-287.5)
P 0.29 0.49
Anaemia
Yes 51 (7.1) 133.0 (43.0-365.0) 158.0 (66.0-515.0)
No 664 (92.9) 130.0 (61.0-256.2) 159.0 (90.0-282.0)
P 0.66 0.44
Obstruction
Yes 106 (13.6) 88.0 (26.0-165.5) 86.0 (20.5-159.0)
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Table 3 Relationship with presenting symptom, help-seeking behaviour and trust in their GP (Continued)
No 675 (86.4) 131.0 (64.0-269.0) 169.0 (94.0-304.5)
P <0.001 <0.001
Nº of initial symptoms
1 417 (58.3) 131.0 (62.5-271.5) 160.5 (91.7-289.7)
2 160 (22.4) 124.0 (59.5-300.2) 158.5 (84.0-330.2)
3 72 (10.1) 143.5 (70.2-246.5) 161.0 (100.0-264.0)
> 3 66 (9.2) 89.0 (40.5-182.0) 117.5 (60.7-223.0)
P 0.12 0.21
Perception of seriousness
Not serious 467 (65.6) 142.0 (67.5-285.5) 171.0 (94.0-316.5)
Quite serious 162 (22.8) 117.0 (61.7-263.2) 153.0 (91.0-296.5)
Very serious 48 (6.7) 83.0 (34.2-129.2) 119.0 (65.0-180.0)
Other 35 (4.9) 110.0 (43.0-229.0) 118.0 (68.0-247.0)
P <0.001 <0.01
Symptom Disclosure
Yes 87 (12.1) 126.0 (56.0-255.0) 155.0 (84.0-282.5)
No 634 (87.9) 152.5 (86.7-340.5) 173.0 (108.5-354.0)
P 0.04 0.06
Help Seeking behaviour
Visited a doctor 494 (68.8) 123.5 (50.7-230.2) 153.0 (78.5-264.0)
Wait for clear up 184 (25.6) 167.5 (88.0-344.7) 187.5 (119.0-273.0)
Other 40 (5.6) 83.0 (33.7-200.0) 95.0 (45.2-232.0)
P <0.001 <0.001
Health services first contact
With my GP 530 (72.7) 147.5 (77.0-278.5) 174.0 (99.0-307.7)
Family Practice emergencies 37 (5.1) 85.5 (30.7-151.2) 114.0 (39.5-179.2)
Hospital emergencies 101 (13.9) 71.0 (22.0-169.7) 84.0 (36.0-204.0)
To my hospital doctor 27 (3.7) 146.0 (96.0-293.0) 190.5 (130.2-344.7)
To Private hospital 14 (1.9) 95.0 (67.7-344.7) 181.0 (113.0-32.0)
Other 20 (2.7) 66.0 (29.5-153.5) 111.0 (44.0-197.0)
P <0.001 <0.001
Would you recommend your doctor?
Yes without any doubt 412 (63.2) 129.0 (59.5-266.5) 156.0 (87.0-289.0)
Probably yes 171 (26.2) 128.0 (56.0-260.0) 159.0 (84.0-307.0)
Probably not 35 (5.4) 130.0 (88.0-213.0) 155.0 (105.0-268.5)
Absolutely not 34 (5.2) 224.0 (133.7-361.5) 228.0 (152.5-362.5)
P 0.02 0.11
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duration of intervals is related to patient attitude toward
the symptom, that is, the interval duration diminishes
when patients disclose the symptom to those close to
them; when they do not wait for symptom clear up, or
when they visit emergency services (either primary care
or hospital). We found an association between trust in
the GP and time to diagnosis or treatment.With regard to GP performance (Table 4), some non-
indicated investigations, such as abdominal transit and
gastroscopy were prescribed very rarely: in only 6 and 16
patients, respectively. GPs requested 109 colonoscopies, 4
rectoscopies and 3 rectosigmoidoscopies. When general
practitioners ask for diagnostic tests of blood, iron, or
blood in the stools, the time to diagnosis or treatment
increases. No relationship has been detected between
Table 4 Relationship of GP performance with delay
N (%) Symptom diagnosis interval Symptom treatment interval
median (p25-p75) median (p25-p75)
(days) (days)
Abdominal exploration
Yes 244 (30.7) 125.0 (67.0-223.0) 155.5 (93.2-259.2)
No 550 (69.3) 149.0 (70.0-280.0) 181.0 (93.7-315.2)
P 0.15 0.09
Rectal examination
Yes 180 (32.8) 129.0 (72.0-250.0) 166.0 (98.2-279.0)
No 369 (67.2) 142.0 (69.5-261.0) 168.0 (91.7-291.0)
P 0.69 0.89
Faecal occult blood
Yes 112 (20.3) 176.0 (89.5-292.0) 202.5 (118.7-324.5)
No 440 (79.7) 128.0 (62.0-248.0) 159.5 (89.7-278.2)
P 0.01 0.01
Blood test
Yes 314 (56.9) 165.0 (88.7-300.7) 188.0 (114.0-323.0)
No 238 (43.1) 103.5 (44.7-223.2) 132.0 (77.5-251.5)
P <0.001 <0.001
Iron deficiency investigation
Yes 117 (21.4) 176.0 (100.0-328.0) 213.0 (116.5-364.0)
No 431 (78.6) 127.0 (63.0-251.5) 160.0 (89.5-272.5)
P <0.01 <0.01
Abdominal XR
Yes 22 (4.0) 180.5 (76.0-257.0) 187.0 (69.0-269.0)
No 528 (96.0) 132.5 (68.5-258.0) 166.0 (94.0-290.0)
P 0.36 0.90
Abdominal Echography
Yes 52 (9.5) 145.5 (73.0-256.0) 165.5 (86.2-261.7)
No 498 (90.5) 136.0 (69.0-258.0) 167.5 (94.0-289.5)
P 0.74 0.74
Barium enema
Yes 38 (6.9) 132.0 (60.0-272.2) 163.0 (96.0-306.0)
No 512 (64.4) 137.5 (70.0-257.7) 167.0 (93.0-287.0)
P 0.71 0.97
Colonoscopy
Yes 109 (19.8) 165.0 (82.5-291.0) 195.0 (132.5-322.0)
No 441 (80.2) 129.5 (64.0-251.0) 157.0 (89.5-282.0)
P 0.02 <0.01
First referral to hospital
Gastroenterology 218 (58.6) 149.5 (77.2-291.2) 185.0 (114.0-317.0)
Surgery 36 (9.7) 153.5 (58.0-291.0) 181.0 (115.2-299.0)
Internal Medicine 13 (3.5) 150.0 (81.0-247.5) 162.5 (106.0-228.2)
Emergency service 89 (23.9) 125.0 (50.0-238.7) 158.0 (82.7-249.0)
Others 16 (4.3) 220.5 (117.5-351.7) 232.0 (138.0-327.0)
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Table 4 Relationship of GP performance with delay (Continued)
P 0.27 0.36
Type of referral
Ordinary 126 (37.5) 181.0 (84.0-303.0) 195.0 (117.2-304.2)
Preferential 99 ( 29.5) 163.0 (85.0-294.0) 193.0 (117.2-317.7)
Urgent 111 (33.0) 111.5 (56.5-208.2) 152.0 (90.0-237.0)
P <0.01 <0.01
Diagnosis suspicion
Yes 184 (54.6) 129.0 (62.0-265.0) 166.0 (92.0-297.0)
No 153 (45.4) 172.5 (86.7-292.0) 195.0 (119.0-317.0)
P 0.06 0.03
CRC suspicion in referral letter
Yes 71 (22.4) 112.0 (63.7-215.7) 153.0 (106.0-247.0)
No 246 (77.6) 166.0 (78.0-304.0) 191.0 (109.0-318.0)
P 0.04 0.03
Number of visits due to CRC symptoms
0 142 (25.9) 08.0 (48.2-205.75) 143.0 (83.0-241.7)
1-2 211 (38.5) 124.5 (59.7-223.0) 153.0 (87.7-256.2)
3-5 138 (25.2) 163.0 (81.0-296.2) 183.0 (104.0-308.5)
>=6 57 (10.4) 264.0 (27.7-393.7) 279.5 (165.0-405.7)
P <0.001 <0.001
Visits in last 12 months before diagnosis
0 7 (1.3) 212.0 (20.0-662.0) 244.0 (57.0-185.0)
1-5 148 (27.0) 126.5 (70.5-229.5) 169.0 (94.0-259.5)
6-12 194 (35.3) 120.0 (60.0-222.0) 153.0 (84.0-255.0)
13-24 139 (25.3) 160.0 (80.0-214.0) 182.5 (108.2.0-358.5)
>=25 61 (11.1) 154.5 (75.2-244.0) 171.0 (92.0-296.0)
P 0.06 0.05
CRC: Colorectal Cancer.
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ination and other image investigations. Shorter SDI and
SDT were observed when the general practitioner referral
to hospital was urgent or when the GP mentioned
suspected diagnosis in the referral. Greater duration to
diagnosis was observed in those with an increasing num-
ber of visits to the GP for symptoms related to CRC and
shorter duration for those frequently attended by their
family or nursing practitioner in the previous year.
Regarding secondary care of CRC cases (Table 5), we
observed that the first contact is made mainly through the
Emergency or Gastroenterology services. Sixty-three per cent
of patients were referred by their GP and a quarter contacted
hospitals by themselves. Shorter intervals are observed when
the patient contacts the emergency service on his or her
own initiative. Additionally, patients with abdominal or rectal
examination, blood test, XT or CT, are diagnosed or treated
earlier; in contrast with patients with MRI.Discussion
This study has used a comprehensive approach in
assessing the factors that underlie the social and clinical
pathway to cancer diagnosis duration in CRC. Findings
show, as in the review of Mitchell et al. [11], the com-
plex relationship between symptom presentation and pa-
tient behaviour regarding perception and response to the
symptoms. Moreover, our results add more information
on the effect in time elapsed from symptom to diagnosis
or treatment of factors such as gender, attitude towards
symptoms, appropriate GP referral and hospital doctor
performance.
First of all, after experiencing the first CRC symptoms,
half of the patients have to wait at least 4 months until
diagnosis. This finding is similar to that described by
others [20-24]. Most notable is the fact that one third
has to wait more than six months to be diagnosed. In ac-
cordance with other findings [20,25], no differences in
Table 5 Performance of hospital doctors and relationship with delay
N (%) Symptom diagnosis Symptom treatment interval
median (p25-p75) median (p25-p75)
(days) (days)
Service of first consultation
Gastroenterology 312 (39.5) 168.0 (90.0-317.5) 199 (124.0-352.0)
General Surgery 52 (6.6) 159.0 (83.5-349.0) 223 (128.0-382.5)
Internal Medicine 36 (4.6) 146.5 (70.7-315.5) 145.5 (90.0-334.0)
Emergency service 363 (46.6) 88.0 (33.5-186.5) 108.0 (52.0-207.5)
Other 26 (3.3) 149.0 (84.0-281.0) 176.0 (103.0-294.5)
P <0.001 <0.001
Contact with hospital
Patient own referral 178 (24.8) 84.0 (27.5-163.5) 111.0 (40.0-210.5)
GP or out of hours service 452 (63.0) 140.0 (70.0-271.0) 171.0 (97.0-306.0)
Referral other specialists 54 (7.5) 126.0 (75.7-352.5) 144.5 (101.0-364.2)




Si 583 (73.6) 111.0 (49.0-238.0) 136.0 (71.0-268.0)
No 209 (26.4) 144.0 (78.2-293.7) 189.0 (111.2-329.5)
P <0.01 <0.001
Rectal Examination
Si 423 (53.3) 118.0 (49,0-224,0) 151.0 (75.0-274.0)
No 370 (46.7) 132.0 (68.5-284.5) 162.0 (92.0-315.0)
P 0.05 0.09
Faecal Blood Test
Si 41 (5.2) 150.0 (72.5-269.5) 193.0 (101.0-362.0)
No 752 (94.8) 127.0 (55.0-253.0) 154.0 (84.0-281.0)
0.68 0.28
Blood Test
Si 573 (72.5) 116.0(49.0-238.0) 139.0 (72.0-262.0)
No 217 (27.5) 144.5(83.0-290.5) 189.0 (119.5-335.2)
P <0.001 <0.001
Iron Investigation
Si 227 (28.7) 137.5 (61.0-286.0) 166.0 (90.0-314.0)
No 563 (71.3) 125.0 (55.5-245.0) 154.0 (83.02-75.5)
P 0.23 0.36
Abdominal XR
Si 274 (34.6) 98.0 (33.0-195.0) 110.0 (48.5-211.5)
No 519 (65.4) 142.0 (72.0-293.0) 177.0 (108.5-318.5)
P <0.001 <0.001
Abdominal Echography
Si 141 (17.8) 113.5 (59.0-241.0) 134.5 (89.2-259.0)
No 652 (82.2) 130.0 (53.0-256.0) 160.5 (83.7-287.5)
P 0.51 0.20
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Table 5 Performance of hospital doctors and relationship with delay (Continued)
Barium Enema
Yes 61 (7.7) 145.0 (76.0-276.0) 179.0 (77.0-343.0)
No 731 (92.3) 124.0 (56.5-251.0) 154.0 (84.0-281.25)
P 0.63 0.63
Barium transit
Yes 11 (1.4) 193.0 (84.5-247.0) 233.0 (47.0-291.0)
No 782 (98.6) 125.5 (57.0-253.0) 154.0 (84.0-282.0)
P 0.54 0.56
Gastroscopy
Yes 92 (11.6) 117.0 (72.0-280.0) 167.0 (92.0-321.0)
No 699 (88.4) 127.0 (53.0-250.5) 154.0 (83.5-275.5)
P 0.41 0.34
Rectoscopy
Yes 35 (4.4) 182.0 (66.0-324.0) 204.0 (103.7-388.0)
No 755 (95.6) 125.5 (56.0-251.0) 154.0 (83.5-280.0)
P 0.19 0.06
Rectosigmoidoscopy
Yes 18 (2.3) 83.0 (43.0-180.0) 116.5 (77.0-221.2)
No 772 (97.7) 128.0 (59.0-255.0) 155.0 (84.0-287.0)
P 0.30 0.46
CT Abdominal Scan
Yes 345 (43.6) 112.0 (45.5-221.5) 128.0 (69.2-244.7)
No 447 (56.4) 142.0 (64.0-280.0) 180.0 (97.5-316.5)
P 0.01 <0.001
Abdominal MRI
Yes 40 (5.1) 194.0 (84.0-403.0) 227.0 (112.5-451.0)
No 751 (94.9) 124.5 (56.0-251.0) 153.5 (83.0-276.7)
P 0.02 0.01
Diagnosis orientation after first Hospital contact
Correct 386 (50.5) 113.5 (55.7-228.5) 146.5 (83.5-263.5)
Appropriate 334 (43.7) 140.0 (58.0-257.5) 158.0 (78.5-297.5)
Inappropriate 44 (5.8) 137.0 (82.0-256.2) 172.0 (111.5-298.2)
P 0.39 0.50
XR Radiography, CT computed tomography, MRI Magnetic Resonance Image.
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detected, although some studies reported longer time for
rectum [26,27].
Women in our study are more likely to experience
longer time to diagnosis than men. These results probably
are related to gender differences in coping with symptoms
and help-seeking behaviour [10,28-30]. Women push men
to see a doctor when they have CRC symptoms while the
women themselves wait for symptoms to clear up [8] be-
cause of fear of having cancer [31]. In fact, waiting for
symptom clear-up was associated in our study with not
being diagnosed or treated promptly.There are no conclusive results on socioeconomic sta-
tus and time elapsed to diagnosis and treatment. Some
studies show longer symptom duration in those patients
with lower social status [22,28,32,33] while our data, in
accordance with others [34,35], could not confirm these
differences. Longer lag time is also seen in those patients
with history of cancer in family members, friends or
colleagues. These factors have not been researched in
depth with regard to CRC and delay [11]. While Ratcliffe
et al. describe no differences in time intervals in those
with or without family history of cancer [36], other
authors have suggested that prior experience of the
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ting medical consultation off [10,37].
Regarding symptom at presentation, we confirmed
that abdominal pain [38-40] and vomiting [32,39] lead
to shorter interval duration. At the same time, as
described by other authors [28,40], our results show that
beliefs that the symptom is serious and symptom dis-
closure to friends and family are strongly associated with
shorter lag times. Again, this could be related to gender, as
women with CRC symptoms generally say nothing to their
families until they have already visited a doctor [10].
Current practice by general practitioners may contrib-
ute to lengthen time to diagnosis. For instance, we
observed that when the GP requests some tests to diag-
nose anemia, the diagnosis process is extended [41]. Un-
fortunately, there is no simple solution to this. When
dealing with a symptom such as anemia, with low predict-
ive value, doctors must confirm non-malignancy before
filling outpatient services with mild pathologies [13,14].
Similarly, misinterpretation of a symptom may result in a
greater number of visits to a doctor before referral to a
specialist [32-34,39-43], and this is a variable associated in
our study with longer time to diagnosis or treatment.
Furthermore, erroneous orientation can be the result
of poor examination and misdiagnosis. Our results show
that the GP only carried out physical examination of one
in three patients; in fact, prior studies have pointed
out insufficient physical examination by the GP, and
no improvement has been observed over time [40-42].
Lack of physical examination and poor investigations by
outpatient or emergency doctors seem to have more
consequences than family doctor performance [32]. This
could be partly due to the fact that a misdiagnosis in a
primary care visit is less important because continuity of
care is highly assured. A misdiagnosis in outpatient care
would be more relevant because a further appointment
is considerably more difficult to make.
On the other hand, the capacity of the GP to form
a suspicion of CRC in the referral has been shown to
be a key factor as it predicts less time to diagnosis.
This may be because when the GP has a clear suspi-
cion, the referral is made more promptly and the re-
sponse of hospital doctors to this type of referral is
faster [44,45].
Strengths and limitations
In contrast with previous studies limited to the assess-
ment of partial time intervals to diagnosis or treatment
(patient or system time intervals), we have been able to
show that these factors also affect total time to diagnosis
or treatment. Our findings show a similar relationship
for time to diagnosis and time to treatment with the
various factors studied. This fact demonstrates that the
variables considered in this study have great influenceon the time to diagnosis and, as a matter of fact, dur-
ation between diagnosis and treatment is relatively less
relevant (>65% of those diagnosed are treated within a
month). The inclusion of a high number of hospitals and
primary care centers could imply high heterogeneity in
data acquisition, but at the same time represents a
complete picture of patterns of care, preventing the se-
lection bias that appears when only a single centre is
included.
The major limitation of this study lies in the lack of a
consistent methodology to precisely measure the date of
symptom presentation. The date of onset of symptoms
obtained from the patient interview has been questioned.
According to some authors, studies fail to consider
existing theories of symptom interpretation. The inter-
pretation of bodily sensations as symptoms is embedded
within a social and cultural context and respondents do
not define time periods in the same way [46]. Therefore,
this date may be quite precise for acute symptoms, such
as rectal bleeding, but difficult to establish for more gen-
eral symptoms such as fatigue [47]. However, other stud-
ies have shown good agreement when comparing
information expressed by patients and doctors [18,48].
Retrospective review of clinical records presents the
same type of problem because it comes from patient infor-
mation provided to doctors. Furthermore, some of the
symptoms described to doctors may go unrecorded, as
highlighted by some authors [49,50]. Patient interviews
conducted during pre or post first treatment could result
in memory biases. The Aarhus statement will facilitate
standardized and uniform definition of studies in this area
[51]. Finally, a trusting relationship with the GP, recorded
after diagnosis, could be spurious as, patient faith in their
GP, could be related to lag time to diagnosis or treatment
[52,53].Conclusions
In conclusion, a substantial proportion of CRC patients
experience long diagnosis and treatment intervals with
potential impact on psychological wellbeing, quality of
life or even survival. Time taken to diagnosis and treat-
ment of colorectal cancer appears to be subject to many
previously suspected factors, symptom presentation, pa-
tient response to symptom, and general practice and sec-
ondary care performance factors.Implications for further research and policy development
Research is needed to develop interventions for use by pri-
mary and secondary care doctors to reduce diagnostic and
treatment time intervals. Gender differences encountered
in our population also deserve to be investigated more
thoroughly. Further research into first-symptom presenta-
tion and concordance between patients and primary and
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methodological issues in cancer delay studies.
The results of this work reveal the existence of areas
for improvement in health care delivered to patients.
Particularly important is to introduce changes to the
existing guidelines whereby physical examination and la-
boratory and image investigations are carried out on all
those who present with lower gastrointestinal symptoms
independently of age, gender or symptom duration. This
would also favour thorough information being included
in the referral letter. If time to diagnosis is to be
reduced, there must be development of interventions
and guidelines to ensure appropriate diagnosis and
examination during both primary and hospital care.
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